Anxious and depressive symptoms in Parkinson's disease: The French cross-sectionnal DoPAMiP study

Movement Disorders

Volumn 25, Issue 2, 2010, Pages 157-166

  Nègre Pagès, Laurence ^a,b   Grandjean, Hélène ^c   Lapeyre Mestre, Maryse ^a   Montastruc, Jean Louis ^a   Fourrier, Annie ^d   Lépine, Jean Pierre ^e   Rascol, Oliver ^a,f  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

^b LN Pharma   (France)

^c INSERM   (France)

^d BORDEAUX UNIVERSITY HOSPITAL   (France)

^e HÔPITAL FERNAND WIDAL   (France)

^f CHU PURPAN   (France)

Author keywords

Antidepressant; Anxiety; Anxiolytic; Depression; Parkinson's disease

Indexed keywords

AMANTADINE; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; CATECHOL METHYLTRANSFERASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; HYPNOTIC AGENT; IMIPRAMINIC ANTIDEPRESSANT; LEVODOPA; MEPROBAMATE; MONOAMINE OXIDASE B INHIBITOR; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; ZOLPICLONE; ZOLPIDEM;

AGED; ANXIETY DISORDER; ARTICLE; CLINICAL FEATURE; COGNITION; COMORBIDITY; COMPARATIVE STUDY; CONTROL GROUP; CONTROLLED STUDY; CORRELATIONAL STUDY; CROSS-SECTIONAL STUDY; DEPRESSION; DRUG USE; FEMALE; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MOTOR DYSFUNCTION; PARKINSON DISEASE; PARKINSONISM; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSPECTIVE STUDY; STRUCTURED QUESTIONNAIRE; UNIFIED PARKINSON DISEASE RATING SCALE;

EID: 77649090082     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22760     Document Type: Article

References (40)

1. Schrag A. Psychiatric aspects of Parkinson's disease-an update. J Neurol 2004;251:795-804.
2. Richard IH. Anxiety disorders in Parkinson's disease. Adv Neurol 2005;96:42-55.
3. Thanvi BR, Munshi SK, Vijaykumar N. Neuropsychiatric non motor aspects of Parkinson's disease. Postgrad Med J 2003;79: 561-565.
4. Menza MA, Robertson-Hoffman DE, Banapace AS. Parkinson's disease and anxiety: comorbidity with depression. Biol Psychiatry 1993;34:465-470.
5. Stein MB, Heuser IJ, Juncos JL, Uhde TW. Anxiety in patients with Parkinson's disease. Am J Psychiatry 1990;147:217-220.
6. Schulman LM, Taback RL, Bean J, Weiner WJ. Comorbidity of the non motor symptoms of Parkinson's disease. Movement Disord 2001;16:507-510.
7. Nuti A, Ceravolo R, Piccinni A. Psychiatric comorbidity in a population of Parkinson's disease patients. Eur J Neurol 2004; 11:315-320.
8. Lauterbach EC, Freeman A, Vogel RL. Correlates of generalized anxiety and panic attacks in dystonia and Parkinson's disease. Cognit Behav Neurol 2003;16:225-233.
9. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361-370.
10. Nègre-Pagès L, Grandjean H, Bouhassira D, Rascol O; on behalf of the DoPaMiP study group. Chronic pain in Parkinson's disease: the cross-sectional French DoPaMiP survey. Mov Disord 2008;23:1361-1369.
11. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:745-752.
12. Folstein MF, Robins LN, Helzer JE. The Mini-Mental State Examination. Arch Gen Psychiatry 1983;40:812.
13. Fahn S, Elton RL; UPDRS Development Committe. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne D, Goldstein M, editors. Recent developments in Parkinson's disease. Florham Park, NJ: Macmillan; 1987. p 153-64.
14. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-442.
15. Skoog I, Lithell H, Hansson L, et al.; SCOPE Study Group. Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on Cognition and Prognosis in the Elderly (SCOPE). Am J Hypertens 2005;18:1052-1059.
16. Leentjens AFG, Lousberg R, Verhey FRJ. The psychometric properties of the Hospital Anxiety and Depression Scale in patients with Parkinson's disease. Acta Neuropsychiatr 2001;13:83-85.
17. Marinus J, Leentjens AF, Visser M, Stiggelbout AM, Van Hilten JJ. Evaluation of the hospital anxiety and depression scale in patients with Parkinson's disease. Clin Neuropharmacol 2002;25:318-324.
18. Leentjens AFG, Dujardin K, Marsh L, et al. Anxiety Rating Scales in Parkinson's Disease: critique and recommandations. Mov Disord 2008;23:2015-2025.
19. Bjelland I, Dahl AA, Tangen Haug T, Neckelmann D. The validity of the Hospital Anxiety and Depression Scale. An updated literatur review. J Psychosom Res 2002;52:69-77.
20. Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989;28:193-213.
21. Fitzpatrick R, Peto V, Jenkinson C, Greenhall R, Hyman N. Health-related quality of life in Parkinson's disease: a study of outpatient clinic attenders. Mov Disord 1997;12:916-922.
22. Organisation mondiale de la Santé (OMS). Classification Statistique Internationale des Maladies et des Problèmes de Santé Connexes (CIM-10), 10th revision, Geneva, 1993.
23. European Pharmaceutical Marketing Research Association (EPHMRA). Anatomical Classification Guidelines. Available at: www.ephmra.org. Last accessed: 2004.
24. Moro E, Scerrati M, Romito LM, Roselli R, Tonali P, Albanese A. Chronic subthalamic nucleus stimulation reduces medication requirements in Parkinson's disease. Neurology 1999;53: 85-90.
25. Hosmer DW, Lemeshow S. Applied logistic regression. Toronto: Wiley; 1989.
26. Reijnders JS, Ehrt U, Weber WE, Aarsland D, Leentjens AF. A systematic review of prevalence studies of depression in Parkinson's disease. Mov Disord 2008;23:183-189.
27. Walsh K, Bennett G. Parkinson's disease and anxiety. Postgrad Med J 2001;77:89-93.
28. Gotham A-M, Brown RG, Marsden CD. Depression in Parkinson's disease: a quantitative and qualitative analysis. J Neurol Neurosurg Psychiatry 1986;49:381-389.
29. Ritchie K, Artero S, Beluche I, et al. Prevalence of DSM-IV psychiatric disorder in the French Elderly population. Br J Psychiatry 2004;184:147-152.
30. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-IV-TR), fourth ed. Washington: American Psychiatric Association; 2000.
31. Bunevicius A, Peceliuniene J, Mickuviene N, Valius L RB. Screening for depression and anxiety disorders in primary care patients. Depress Anxiety 2007;24:455-460.
32. Olssøn I, Mykletun A, Dahl AA. The Hospital Anxiety and Depression Rating Scale: a cross-sectional study of psychometrics and case finding abilities in general practice. BMC Psychiatry 2005 Dec 14;5:46.
33. Herrmann C. International experiences with the hospital anxiety and depression scale; a review of validation data and clinical results. J Psychosom Res 1997;42:17-41.
34. Schrag A, Barone P, Brown RG, et al. Depression rating scales in Parkinson's disease: critique and recommendations. Mov Disord 2007;22:1077-1092.
35. Lépine JP, Bouchez S. Epidemiology of depression in elderly. Int Clin Psychopharmacol 1998;13(Suppl 5):S7-S12.
36. Lépine JP, Gasquet I, Kovess V, et al. Prevalence and comorbidity of psychiatric disorders in the French general population. Encephale 2005;31:182-194.
37. Tyrer P, Baldwin D. Generalised anxiety disorder. Lancet 2006;368:2156-2166.
38. Djernes JK. Prevalence and predictors of depression in populations of elderly: a review. Acta Psychiatr Scand 2006;113:372-387.
39. Aiken CB. Pramipexole in psychiatry: a systematic review of the literature. J Clin Psychiatry 2007;68:1230-1236.
40. Corrigan M, Denahan A, Wright E, Ragual R, Evans D. Comparison of pramlipexole, fluoxetine and placebo in patients with major depression. Depress Anxiety 2000;11:58-65.